 Home > Medical News > Medicines Company News > Sirnaomics will report on the latest developments of the GalAhead® therapy delivery platform and related projects at two future industry academic conferences

Sirnaomics will report on the latest developments of the GalAhead® therapy delivery platform and related projects at two future industry academic conferences

 Last Update: 2022-10-25
 Source: Internet
 Author: User

Tags

company financial report

beam therapeutics stock

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Sirnaomics Ltd.
(the "Company", "Sirnaomics", stock code: 2257.
HK), is an industry-leading biopharmaceutical company
focused on the exploration and development of RNAi therapeutics.
Sirnaomics announced that the company will present the latest progress on GalAhead™, the proprietary GalNAc-RNAi therapy delivery platform, and its programs at two industry conferences in Boston: the RNA Leaders USA Congress and the 18th Drug Discovery Innovation Programme
。 The RNA Leaders USA Congress will be held
October 18-19 at The Colonnade Hotel.
The 18th annual Drug Discovery Innovation Program will be held
October 26-27 at The Westin Copley Place.

Details of the presentation at the American RNA Leadership Conference:

● Speech topic: GalAhead™: A novel therapeutic GalNAc-RNAi delivery platform that can downregulate single or multiple genes

Speaker: Dr.
Dmitry Samarsky, Chief Technology Officer, Sirnaomics

● Date/Time: Wednesday, October 19, 2022 at 2:10 p.
m.
ET

● Speech content:

Introducing GalAhead, Sirnaomics' novel therapy GalNAc-RNAi™ delivery platform

GalAhead™ technology has been validated in vivo and in vitro

Report on the progress of GalAhead-based™ treatment programs

Details of the 18th Drug Discovery Innovation Program Speech:

● Speech topic: A novel therapeutic GalNAc-RNAi delivery platform that can down-regulate single or multiple genes

Speaker: Dr.
Dmitry Samarsky, Chief Technology Officer, Sirnaomics

● Date/Time: Wednesday, October 26, 2022 at 04:00 PM EDT

● Speech content:

Introducing GalAhead, Sirnaomics' novel therapy GalNAc-RNAi™ delivery platform

GalAhead™ technology has been validated in vivo and in vitro

Report on the progress of GalAhead-based™ treatment programs

={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"Share to:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)];

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.